Emergent BioSolutions Inc. (NYSE:EBS) announces that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines. As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene.
Read the full article: Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International //
Source: https://www.globenewswire.com/news-release/2025/03/10/3039816/33240/en/Emergent-BioSolutions-Announces-Sale-of-Baltimore-Bayview-Manufacturing-Site-to-Syngene-International.html